ICAM1 and plasma cell myeloma: Retrospective analysis of bone marrow samples obtained from this trial revealed increased infiltration of CD56dimCD16+ NK cells exhibiting higher expression of the adhesion molecule, CD54 (ICAM-1), and concomitant reduction in CD45dimCD138+ myeloma cells at cycle 1 day 22, as compared to baseline (25).